Malignant Peritoneal Mesothelioma

Chapter

Abstract

One of the first descriptions of malignant peritoneal mesothelioma (MPM) was in a case report published 100 years ago [1]. In 1972, Moertel published a review of MPM and described the clinical presentation, histological features, and biological behavior of 169 patients [2].

References

  1. 1.
    Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. Med Gen Med. 2007;9:32.Google Scholar
  2. 2.
    Moertel CG. Peritoneal mesothelioma. Gastroenterology. 1972;63(2):346–50.PubMedGoogle Scholar
  3. 3.
    Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576–88.CrossRefPubMedGoogle Scholar
  5. 5.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. EJSO. 2006;32:686–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Wagner JC, Gilson JC, Berry G, Timbrell V. Epidemiology of asbestos cancers. Br Med Bull. 1971;27(1):71–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51:804–11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Newhouse ML, Thopson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. 1965. Br J Ind Med. 1993;50:769–78.PubMedGoogle Scholar
  11. 11.
    Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000;44:565–601.CrossRefPubMedGoogle Scholar
  12. 12.
    Peterson JT, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma: a review. Cancer. 1984;54:951–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, Chan CC, Wen CP, Furuya S, Higashi T, Chien LC, Ohtaki M. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet. 2017;369(9564):844–9.Google Scholar
  14. 14.
    Weill H, Hughes JM, Chrug AM. Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61:438–41.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stock RJ, YS F, Carter JR. Malignant peritoneal mesothelioma following radiotherapy for seminoma of the testis. Cancer. 1979;44:914–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Baris YI, Grandjean P. Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite. J Natl Cancer Inst. 2006;98(6):414–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Hueper WC. Cancer induction by polyurethane and polysilicone plastics. J Natl Cancer Inst. 1964;33:1005–27.PubMedGoogle Scholar
  18. 18.
    Shivapurkar N, Weithege T, Wistuba II, Milchgrub S, Muller KM, Gazdar AF. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer. 2000;85:743–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, Frazer KA, Lowy AM, Harismendy O. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med. 2015;13:122.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Park JY, Kim KW, Kown HJ, Park MS, Kwon GU, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR. 2009;191:814–21.CrossRefGoogle Scholar
  21. 21.
    Alexander HR, Burk AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7(1):79–86.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981;8(3):313–20.PubMedGoogle Scholar
  23. 23.
    Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Reuter K, Raptopoulos V, Reale F, Krolikowski FJ, D’Orsi CJ, Graham S, Smith EH. Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. AJR. 1983;140(6):1189–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103(4):839–49.CrossRefPubMedGoogle Scholar
  26. 26.
    Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol. 2011;35(1):55–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012;19:1394–401.CrossRefPubMedGoogle Scholar
  28. 28.
    Hassan R, Remaely AT, Sampson ML, Zhang J, Cox DD, Pingpak J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Sebbag G, Yan H, Shmookler M, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Husain A, Colby TV, Travis WD, Wick M. Guidelines for pathologic diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2009;133:1317–31.PubMedGoogle Scholar
  32. 32.
    Lee M, Alexander HR, Burke A. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology. 2013;45(5):464–73.CrossRefPubMedGoogle Scholar
  33. 33.
    Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson AG, Roggli V, Travis WD, Wick M, International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–67.CrossRefPubMedGoogle Scholar
  34. 34.
    Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215–20.CrossRefPubMedGoogle Scholar
  35. 35.
    Husain AN, Miraza MK, Gibbs A, Hiroshima K, Chi Y, Boumendjel R, Stang N, Krausz T, Galateau-Salle F. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas. In international collaborative study. Lung Cancer. 2014;83:324–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117(9):1855–63.CrossRefPubMedGoogle Scholar
  38. 38.
    Chua TC, Chong CH, Morris DL. Peritoneal mesothelioma: current status and future directions. Surg Oncol Clin N Am. 2012;21:635–43.CrossRefPubMedGoogle Scholar
  39. 39.
    Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822–31.CrossRefPubMedGoogle Scholar
  40. 40.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.CrossRefPubMedGoogle Scholar
  41. 41.
    Yan TD, Deraco M, Barrati D, Kusamua S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Moahmed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.CrossRefPubMedGoogle Scholar
  42. 42.
    Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.CrossRefPubMedGoogle Scholar
  43. 43.
    Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21:3947–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22(5):1680–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Sugarbaker PH, Turaga KK, Alexander R, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–35.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Elizabeth Poli
    • 1
  • Ashvin Rangole
    • 2
  • Kiran K. Turaga
    • 1
  1. 1.Department of Surgical OncologyChicago University Hospital MedicineChicagoUSA
  2. 2.Department of Surgical OncologyCHL-CBCC Cancer CentreIndoreIndia

Personalised recommendations